Physician profile
Ariel Nassim
NPI 1780959866
$9,298.41
in general payments reported to CMS, 2019-2025
47 companies · $1,855 in 2025
The $1,855 reported for 2025 was more than what 97% of Sports Medicine (Internal Medicine) providers received nationally (typical 2025 total: $99.49).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $648 · 2020: $725 · 2021: $901 · 2022: $1,497 · 2023: $1,762 · 2024: $1,910 · 2025: $1,855.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,516 · Education: $11.56.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,516.42 |
| Education | $11.56 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,754.35 | 2019-2025 | |
| Astrazeneca Pharmaceuticals Lp | $1,453.30 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Novo Nordisk INC | $1,183.80 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Amgen INC. | $916.08 | 2019-2025 | Repatha, Otezla, Otezla |
| Lilly USA, LLC | $310.50 | 2022-2025 | Mounjaro, Zepbound, Jardiance |
| Horizon Therapeutics Plc | $304.76 | 2019-2022 | |
| Pfizer INC. | $258.69 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $209.38 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $194.35 | 2022-2025 | |
| Vertex Pharmaceuticals Incorporated | $185.35 | 2025 | |
| Kowa Pharmaceuticals America, INC. | $183.57 | 2022-2023 | Seglentis |
| Ferring Pharmaceuticals INC. | $183.57 | 2019-2025 | Euflexxa |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $182.09 | 2020-2025 | Xifaxan, Trulance |
| Astellas Pharma US INC | $171.50 | 2023-2025 | Veozah, Myrbetriq |
| Esperion Therapeutics, INC. | $149.67 | 2022-2025 | Nexletol |
Show all 47 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $130.86 | 2019-2024 | Jardiance, Ofev, Synjardy |
| E.R. Squibb & Sons, L.L.C. | $122.19 | 2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $118.14 | 2024-2025 | Caplyta |
| Depuy Synthes Sales INC. | $112.36 | 2019-2023 | Orthovisc |
| Bioventus LLC | $106.47 | 2019-2024 | Supartz Fx Sodium Hyaluronate |
| Inspire Medical Systems, INC. | $95.18 | 2024 | Inspire |
| Biohaven Pharmaceutical Holding Company Ltd. | $91.31 | 2022 | |
| Mannkind Corporation | $84.25 | 2023 | Afrezza |
| Axsome Therapeutics, INC. | $79.56 | 2025 | Symbravo |
| Allergan, INC. | $65.56 | 2019-2021 | |
| Idorsia Pharmaceuticals US INC | $60.30 | 2023 | Quviviq |
| Sumitomo Pharma America, INC. | $57.83 | 2025 | Gemtesa |
| Exact Sciences Corporation | $50.01 | 2023-2024 | Cologuard Collection Kit |
| Glaxosmithkline, LLC. | $49.56 | 2023-2025 | Shingrix, Arexvy, Trelegy Ellipta |
| Electromed, INC. | $42.97 | 2023 | Smartvest |
| Ardelyx, INC. | $39.98 | 2024 | Ibsrela |
| Genentech USA, INC. | $34.04 | 2020 | |
| Philips North America LLC | $30.01 | 2020 | |
| Pacira Pharmaceuticals Incorporated | $28.13 | 2023 | Zilretta, Iovera |
| Lundbeck LLC | $25.31 | 2025 | Rexulti |
| Corcept Therapeutics | $25.00 | 2025 | Korlym |
| Renalytix Ai, INC. | $24.96 | 2024 | Kidneyintelx Blood Collection Convenience Kit |
| Phathom Pharmaceuticals, INC. | $24.15 | 2024 | Voquezna |
| Azurity Pharmaceuticals, INC. | $23.23 | 2024 | Edarbi |
| Dexcom, INC. | $18.82 | 2021 | |
| Amarin Pharma, INC. | $18.67 | 2021 | |
| Scilex Pharmaceuticals INC. | $18.62 | 2025 | |
| Currax Pharmaceuticals LLC | $17.85 | 2025 | Contrave |
| Daiichi Sankyo INC. | $17.37 | 2020 | |
| Arbor Pharmaceuticals, INC. | $16.41 | 2021 | |
| Shield Therapeutics INC | $15.79 | 2025 | |
| Gilead Sciences, INC. | $12.56 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ariel Nassim listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.